BamSEC and AlphaSense Join Forces
Learn More

BridgeBio Pharma Inc. – Indentures

NASDAQ: BBIO    
Share price (6/25/26): $69.69    
Market cap (6/25/26): $13.6 billion
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.4
from S-3ASR 41 pages BridgeBio Pharma, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [•], 202[•] Subordinated Debt Securities
12/34/56
EX-4.3
from S-3ASR 41 pages BridgeBio Pharma, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [•], 202[•] Senior Debt Securities
12/34/56
EX-4.1
from 8-K 115 pages BridgeBio Pharma, Inc. and U.S. Bank Trust Company, National Association, as Trustee Indenture Dated as of January 21, 2026 0.75% Convertible Senior Notes Due 2033
12/34/56
EX-4.1
from 8-K 115 pages BridgeBio Pharma, Inc. and U.S. Bank Trust Company, National Association, as Trustee Indenture Dated as of February 28, 2025 1.75% Convertible Senior Notes Due 2031
12/34/56
EX-4.5
from S-3ASR 41 pages BridgeBio Pharma, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [•], 202[•] Subordinated Debt Securities
12/34/56
EX-4.4
from S-3ASR 41 pages BridgeBio Pharma, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [•], 202[•] Senior Debt Securities
12/34/56
EX-4.3
from 10-K 7 pages Description of Capital Stock of BridgeBio Pharma, Inc
12/34/56
EX-4.3
from 10-K 6 pages Description of Capital Stock of BridgeBio Pharma, Inc
12/34/56
EX-4.1
from 8-K 110 pages BridgeBio Pharma, Inc. and U.S. Bank National Association, as Trustee Indenture Dated as of January 28, 2021 2.25% Convertible Senior Notes Due 2029
12/34/56
EX-4.5
from S-3ASR 37 pages BridgeBio Pharma, Inc. Issuer and [Trustee], Trustee Indenture Dated as of [ ] Subordinated Debt Securities
12/34/56
EX-4.4
from S-3ASR 35 pages BridgeBio Pharma, Inc. Issuer and [Trustee], Trustee Indenture Dated as of [ ] Senior Debt Securities
12/34/56
EX-4.1
from 8-K 104 pages BridgeBio Pharma, Inc. and U.S. Bank National Association, as Trustee Indenture Dated as of March 9, 2020 2.50% Convertible Senior Notes Due 2027
12/34/56
EX-4.4
from 10-K 4 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.1
from 8-K 32 pages Registration Rights Agreement
12/34/56
EX-4.3
from S-1/A 22 pages Registration Rights Agreement
12/34/56
EX-4.1
from S-1/A 2 pages Indenture or similar
12/34/56
EX-4.3
from S-1 23 pages Registration Rights Agreement
12/34/56
EX-4.2
from S-1 102 pages Fourth Amended and Restated Limited Liability Company Agreement of BridgeBio Pharma LLC a Delaware Limited Liability Company Dated as of November 20, 2018
12/34/56
EX-4.3
from DRS/A 23 pages Registration Rights Agreement
12/34/56
EX-4.2
from DRS/A 102 pages Fourth Amended and Restated Limited Liability Company Agreement of BridgeBio Pharma LLC a Delaware Limited Liability Company Dated as of November 20, 2018
12/34/56